Part 1: Introduction -- Chapter 1. Alzheimer's Disease -- Chapter 2. Rates of Dementia -- Chapter 3. Biomarkers and Clinical Endpoints -- Chapter 4. Ocular Biomarkers -- Part 2: Diagnosis -- Chapter 5. Biochemical and Neuroimaging -- Chapter 6. Cognitive Decline -- Chapter 7. EEG/ERP -- Chapter 8. Eye Tracking -- Chapter 9. Light Intervention -- Chapter 10. Retina -- Chapter 11. Tears -- Chapter 12. Telemedicine -- Chapter 13. Virtual Reality -- Part 3: Treatment -- Chapter 14. Recruiting Trials in the US -- Chapter 15. Not Yet Recruiting Trials in the US.

This book is a compendium of the worldwide studies of Alzheimer’s disease utilizing the eye as a biomarker, or as a treatment method, that are registered with the United States National Institutes of Health website, clinicaltrials.gov. Clinicaltrials.gov is the largest listing of research studies in the world. The study titles are provided, as is the country of origin and the Clinical Trial Number in order to make it easier for the reader to locate the study and obtain further information. New drug development is costly and time consuming. If through the use of biomarkers, study durations and research costs decrease, there is a greater possibility of a new and effective drug to treat this devastating disease. The eye offers the possibility of early diagnosis and of treatment. Alzheimer’s Disease and the Eye is a valuable resource for ophthalmologists, optometrists, other physicians, and researchers.